Document is current
Any future updates will be listed below
-
Authors
Hurley, Rachel M.
Wagner, Jill M.
Kanakkanthara, Arun
Venkatachalam, Annapoorna
Deisinger, Aaron M.
Correia, Cristina
Schneider, Paula A.
Peterson, Kevin L.
Macon, Elaine P.
Heinzen, Ethan P.
Sanjiv, Kumar
Hou, Xiaonan
Becker, Marc A.
Maurer, Matthew J.
Larson, Melissa C.
Swisher, Elizabeth M.
Li, Hu
Oberg, Ann L.
Weroha, S. John
Berglund, Ulrika Warpman
Helleday, Thomas
Kaufmann, Scott H.
Hendrickson, Andrea E. Wahner
-
Funding
Funding for this research was provided by:
Minnesota Ovarian Cancer Alliance
National Institutes of Health (T32 GM065841, P50 CA136393, P50 CA136393, P50 CA136393, P50 CA136393, P50 CA136393, P50 CA136393)
Mayo Foundation for Medical Education and Research
Swedish Cancer Society
Mayo-Karolinska Institutet Collaborative Grant
Fred C. and Katherine B. Andersen Foundation
- License Information
-
More Information
Article History
Received: 5 October 2024
Accepted: 10 June 2025
First Online: 23 June 2025
Declarations
:
: PDXs were generated under protocols approved by the Mayo Clinic Institutional Review Board (approval # 09-008768) and Mayo Clinic Animal Care and Use Committee (approval # A37615). Treatments with carboplatin and karonudib were conducted under the aegis of Mayo Clinic Animal Care and Use Committee protocol A00005570-20.
: Not applicable.
: U.W.B., T.H. and K.S. are shareholders in Oxcia AB. In addition, U.W.B. is CEO and board member of Oxcia AB; T.H. is board member of Oxcia AB; and A.W.H. serves on the advisory board of Oxcia AB. The other authors report no conflicts of interest.
